The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis
OBJECTIVES: To perform a meta-analysis of the risk of relapse after discontinuation of anti-
tumor necrosis factor (anti-TNF) therapy in patients with Crohn's disease (CD) and ulcerative …
tumor necrosis factor (anti-TNF) therapy in patients with Crohn's disease (CD) and ulcerative …
Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti‐TNF therapy
JP Gisbert, AC Marín… - Alimentary pharmacology & …, 2015 - Wiley Online Library
Background The discontinuation of anti‐tumour necrosis factor (anti‐TNF) treatment in
inflammatory bowel disease (IBD) patients in remission could be considered. Aim To …
inflammatory bowel disease (IBD) patients in remission could be considered. Aim To …
Optimal stopping for response-guided dosing
J Kotas - Networks and Heterogeneous Media, 2019 - aimsciences.org
In response-guided dosing (RGD), the goal is to make optimal dosing decisions based on
the stochastic evolution of a patient's disease condition. Typically, RGD is formulated as a …
the stochastic evolution of a patient's disease condition. Typically, RGD is formulated as a …
Cessation of Biologics: Can It Be Done?
HH Shim, CH Seow - Treatment of Inflammatory Bowel Disease with …, 2018 - Springer
Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory conditions of the
gastrointestinal tract characterized by a relapsing and remitting course which may lead to …
gastrointestinal tract characterized by a relapsing and remitting course which may lead to …
Dynamic, convex, and robust optimization with Bayesian learning for response-guided dosing
J Kotas - 2016 - digital.lib.washington.edu
Medical treatment commonly involves the administration of drug doses at multiple time-
points. Intuitively, the higher the doses, the higher the likelihood of disease control as well as …
points. Intuitively, the higher the doses, the higher the likelihood of disease control as well as …
Evolución clínica tras la suspensión de infliximab en pacientes con colitis ulcerosa en remisión profunda
CM Villafranca, MTB Rodríguez, JO de Zárate… - Gastroenterología y …, 2016 - Elsevier
Introducción Infliximab (IFX) es efectivo en la colitis ulcerosa (CU) y en obtener la curación
de la mucosa (CM). Se conoce poco el papel que juega la CM en la evolución posterior de …
de la mucosa (CM). Se conoce poco el papel que juega la CM en la evolución posterior de …